3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
3
Carcinoma, Transitional Cell
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Cisplatin
21
pembrolizumab
16
Gemcitabine
16
Paclitaxel
15
Radiotherapy
14
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
9
Cetuximab
9
Magnetic Resonance Spectroscopy
8
Radiation
7
padeliporfin
6
Specimen Handling
6
Oxaliplatin
6
Fluorouracil
6
Drug Therapy
6
Docetaxel
6
Capecitabine
6
Bevacizumab
6
anlotinib
5
Nivolumab
5
Irinotecan
5
Erlotinib Hydrochloride
5
Celecoxib
5
poly ICLC
4
fludarabine
4
Standard of Care
4
Sorafenib
4
Leucovorin
4
Ipilimumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma
×
vinflunine
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled